AbbVie Announces That 9 Canadian Provinces Have Provided Accelerated Public Coverage Of EPKINLY, A Treatment For Adult Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
AbbVie Announces That 9 Canadian Provinces Have Provided Accelerated Public Coverage Of EPKINLY, A Treatment For Adult Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
AbbVie (NYSE:ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large B-cell lymphoma (R/R DLBCL) not otherwise specified, DLBCL transformed from indolent lymphoma, high grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL) or follicular lymphoma Grade 3B (FLG3b) and is indicated after two or more lines of systemic therapy in patients who have previously received or are unable to receive CAR-T cell therapy.1 EPKINLY has been issued market authorization with conditions, pending the results of trials to verify its clinical benefit.
艾伯維公司（紐交所：ABBV）今日宣佈，國內九個省份已加快公佈EPKINLY的覆蓋範圍。EPKINLY是一種用於成年複發性或難治性瀰漫大b細胞淋巴瘤（R/R DLBCL），原發於非特指的DLBCL，由溫和淋巴瘤轉變的DLBCL，高級別b細胞淋巴瘤（HGBCL），原發性縱隔b細胞淋巴瘤（PMBCL）或濾泡性淋巴瘤G3b（FLG3）患者的治療藥物，指示在之前接受過兩種或更多種全身治療的患者中使用，這些患者之前曾接受過或無法接受CAR-T細胞療法。EPKINLY已獲得有條件的市場授權，待驗證其臨床受益的試驗結果後。
In August, EPKINLY was first listed, with specific reimbursement criteria, in Ontario and Quebec, and is now publicly funded in almost all remaining provinces, including Nova Scotia, British Columbia, Saskatchewan, Manitoba, and Newfoundland & Labrador.
八月份，EPKINLY首次被列入，具體報銷標準，在安大略省和魁北克，如今幾乎所有其他省份，包括新斯科舍省、不列顛哥倫比亞省、薩斯喀徹溫省、曼尼托巴省和紐芬蘭和拉布拉多省，都在公共資助範圍內。
譯文內容由第三人軟體翻譯。
